|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Terms of Use and General Disclaimer
As a user of this site, I agree to the following terms of use and general disclaimer:
Partial support for this website comes from unrestricted educational grants from Genentech BioOncology and Sanofi-Aventis. The commentary and opinions expressed are those of the presenters/speakers and are not to be construed as those of Breast Cancer Update or its grantors. As part of this website, materials and presentations may include information regarding the use of drugs that may be inconsistent with or outside the approved labeling for these products. Physicians should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. Please refer to the US product information for complete information about each drug.
Breast Cancer Update is designed for educational purposes only and is not engaged in rendering medical advice or professional services. Breast Cancer Update does not provide individualized medical diagnosis, treatment or advice, nor do we recommend specific therapies or prescribe medication for anyone using our website. The content of this website is for general informational purposes only. Patients seeking information should confirm information with their doctor or with other sources. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
This website and materials presented are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, without written permission from the copyright owner.
 |
 |
TOPICS
Adjuvant Chemotherapy for Patients with HER2-Negative Disease
Adjuvant Systemic Therapy for Patients with HER2-Positive Disease
Adjuvant Therapy for Elderly Patients with HER2-Positive Disease
Adjuvant Trial Evaluating Trastuzumab and/or Lapatinib in HER2-Positive Disease
- Select publications
Role of Bevacizumab for Patients with HER2-Negative Metastatic Disease
Adjuvant Trial Combining Bevacizumab with Trastuzumab
Optimizing First-Line Systemic Therapy for Patients with ER-Positive, HER2-Positive Metastatic Disease
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
